OrphanPulse Wk 40: A First Approval in MCT8 Deficiency, and a Missed Pivotal Headed for Filing
One first approval, and one missed pivotal headed for filing anyway: the week tested what rare disease evidence can carry.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
Merck and Daiichi Pulled an ADC Filing as GSK Paid $110 Million for a KRAS Payload
ICER Says AstraZeneca’s $10,950 Baxfendy Is Worth $1,400 to $2,500 a Year
Genentech Paid $100 Million for Alector’s Parkinson’s Enzyme but Not Its Brain Shuttle
Shionogi Paid 29 Times Sales for IntraBio, 17 Days After AQNEURSA’s Second FDA Approval
CSL Paid $355 Million and Gave Up 45% of the Profits to Win a Claudin-1 Antibody
